ABX 002
Alternative Names: ABX-002Latest Information Update: 26 Jul 2024
At a glance
- Originator Autobahn Therapeutics
- Class Acetamides; Antidepressants; Behavioural disorder therapies; Neuroprotectants; Small molecules
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Bipolar depression; Major depressive disorder
- Preclinical Adrenomyeloneuropathy
- Research Multiple sclerosis
Most Recent Events
- 24 Jul 2024 Autobahn plans a phase II trial for Major depressive disorder and Bipolar depression (Adjunctive treatment) in the second half of 2024
- 29 May 2024 Phase-I clinical trials in Bipolar depression (Adjunctive treatment) (PO) prior to May 2024
- 07 Nov 2023 Pharmacokinetics and adverse event data from a phase I trial in Major depressive disorder released by Autobahn Therapeutics